Orchestra BioMed Holdings, Inc.·4

Jun 2, 4:28 PM ET

Hochman David P 4

Research Summary

AI-generated summary

Updated

Orchestra BioMed (OBIO) CEO David P. Hochman Buys 5,000 Shares

What Happened

  • David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed (OBIO), acquired 5,000 shares in an open-market purchase on 2026-06-01. The reported weighted-average price was $3.83, for an aggregate value of about $19,150.

Key Details

  • Transaction type: Purchase (code P) — open market/private purchase.
  • Transaction date: 2026-06-01; Form 4 filed 2026-06-02 (timely filing).
  • Price reported: $3.83 weighted average; actual trade prices ranged from $3.80 to $3.91 (footnote F1).
  • Shares owned after transaction: Not specified in the provided filing details.
  • Footnote: The filing notes multiple trades within the $3.80–$3.91 range and offers to provide per-price breakdown on request.

Context

  • Purchases by company insiders (especially CEOs) are often viewed as a stronger signal than routine sales because they require personal capital outlay, though filings do not reveal motivation. This was a direct purchase, not an option exercise, gift, or tax withholding.